Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AVRO
- Price
- -
- Stock movement down
- -0.36 (-2.00%)
- Company name
- AVROBIO Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 65.99M
- Ent value
- -21.26M
- Price/Sales
- 18.34
- Price/Book
- 0.74
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 2.18
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 32.43%
- 3 year return
- -46.39%
- 5 year return
- -35.78%
- 10 year return
- -
Last updated: 2024-12-16
DIVIDENDS
AVRO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 2.18 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 18.34 |
| Price to Book | 0.74 |
| EV to Sales | -5.91 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.74M |
| EPS (TTM) | 0.68 |
| FCF per share (TTM) | -1.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.60M |
| Gross profit (TTM) | 920.00K |
| Operating income (TTM) | 27.83M |
| Net income (TTM) | 30.31M |
| EPS (TTM) | 0.68 |
| EPS (1y forward) | -0.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 25.57% |
| Operating margin (TTM) | 773.51% |
| Profit margin (TTM) | 842.30% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 90.76M |
| Net receivables | 0.00 |
| Total current assets | 91.84M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 110.00K |
| Total assets | 92.35M |
| Accounts payable | 243.00K |
| Short/Current long term debt | 224.00K |
| Total current liabilities | 3.51M |
| Total liabilities | 3.51M |
| Shareholder's equity | 88.84M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -50.48M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -50.48M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 34.11% |
| Return on Assets | 32.82% |
| Return on Invested Capital | 34.03% |
| Cash Return on Invested Capital | -56.67% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| AVRO | S&P500 | |
| Current price drop from All-time high | -97.21% | - |
| Highest price drop | -98.90% | -56.47% |
| Date of highest drop | 17 May 2023 | 9 Mar 2009 |
| Avg drop from high | -79.15% | -11.07% |
| Avg time to new high | 89 days | 12 days |
| Max time to new high | 1438 days | 1805 days |
COMPANY DETAILS
Marketcap
65.99M
Marketcap category
Small-cap
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Employees
13
Website
Investor relations
-
SEC filings
CEO
Geoff MacKay
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner